Skip to main content
. 2022 Dec 7;9:1247–1261. doi: 10.2147/JHC.S383922

Figure 2.

Figure 2

Timeline of United States Food and Drug Administration approvals for the systemic treatment of hepatocellular carcinoma. Used with permission of Annual Review, Inc., from Hepatocellular Carcinoma Immunotherapy, Sperandio RC, Pestana RC, Miyamura BV, Kaseb AO, Volume 73, 2022; permission conveyed through Copyright Clearance Center, Inc.59